A Novartis castoff drug gets new life at an Atlas-backed startup looking to blaze a trail in obesity
After decades of failure, the obesity field is finally seeing some major progress with the success of a stable of GLP-1 diabetes drugs showing clinical benefit. A small biotech thinks it has something new to offer in that space with an older drug, and investors like what they see so far.
Versanis Bio launched Tuesday with a $70 million A round backed by biotech blue-chippers Atlas Venture and Medicxi with lead candidate bimagrumab, an in-licensed Novartis drug originally targeting muscle weakness, gearing up for a Phase II study in obesity.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.